2025年全球可吸入生技药品市场报告

预计未来几年可吸入生技药品市场规模将快速成长；到2029年，其规模将成长至59亿美元，复合年增长率为16.0%。预测期内的增长可归因于全球老龄化人口的不断增长、新兴市场医疗基础设施的不断扩张、对生技药品治疗的监管支持力度的不断加大以及传染性呼吸道疾病病例的不断增加。预计这段时期的主要趋势包括药物传输系统的进步、智慧吸入器技术的整合、气雾剂科学的创新、生物製药的发展以及奈米颗粒载体的进步。

预计未来几年，呼吸系统疾病的日益普及将显着促进可吸入生技药品市场的成长。呼吸系统疾病包括影响肺部和呼吸系统其他组成部分（包括气道、鼻腔和肺）的疾病和病症。这些疾病的增加主要是由于空气污染的加剧，空气污染使人们暴露于有害颗粒物和污染物中，加剧了气喘、慢性阻塞性肺病(COPD) 和肺癌等疾病。可吸入生技药品对这些疾病尤其有效，因为它们可以将标靶治疗直接作用于肺部，减少发炎并改善肺功能，同时限制全身副作用。例如，2024 年 6 月，澳洲政府机构澳洲健康与福利研究所报告称，到 2023 年，COPD 将占总疾病负担的 3.6%，占呼吸系统疾病负担的 50%。因此，呼吸系统疾病的增加正在显着推动可吸入生技药品市场的发展。

吸入式生技药品市场的主要企业正专注于开发吸入式胰岛素等突破性解决方案，以提高患者的依从性并提供更快的血糖控制。吸入式胰岛素是透过吸入将胰岛素直接输送到肺部血液中，而不是透过注射或胰岛素帮浦。在这种方法中，粉状或气雾化的胰岛素被吸入并从肺部吸收，迅速进入血液并调节血糖值。例如，2025年2月，印度製药公司Cipla Limited获得了中央药品标准控制组织对世界上最快的吸入式胰岛素Afrezza的监管批准，该药物为患有1型和2型糖尿病的成年人提供了无针核准。这种超速效胰岛素在吸入后12-15分钟内开始起效，并且非常接近模拟胰岛素对餐后的自然反应，从而改善血糖控制。吸入式胰岛素为每日註射提供了更舒适的替代方案，特别是对于那些对注射感到焦虑的患者，并提高了对胰岛素治疗的依从性。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场 - 宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

• 全球可吸入生技药品PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素与限制因素）
• 最终用途产业分析
• 全球可吸入生技药品市场：成长率分析
• 全球吸入式生技药品市场表现：规模与成长，2019-2024
• 全球可吸入生技药品市场预测：2024-2029 年、2034 年规模与成长
• 可吸入生技药品的全球总目标市场（TAM）

第六章市场区隔

• 全球可吸入生技药品市场类型、绩效及预测（2019-2024、2024-2029、2034）
• 胜肽和蛋白质
• 疫苗
• 单株抗体
• 基于RNAi的治疗方法
• 其他类型
• 全球吸入性生技药品市场（依剂型划分）：历史资料及预测（2019-2024 年、2024-2029 年、2034 年）
• 干粉吸入器
• 定量喷雾吸入器
• 喷雾器
• 其他剂型
• 全球可吸入生技药品市场（依通路）：历史资料及预测（2019-2024 年、2024-2029 年、2034 年）
• 医院药房
• 零售药局
• 网路药局
• 全球可吸入生技药品市场的应用、绩效及预测（2019-2024、2024-2029、2034）
• 呼吸系统疾病
• 糖尿病
• 癌症
• 其他用途
• 全球可吸入生技药品市场，依胜肽及蛋白质类型细分，绩效及预测，2019-2024 年、2024-2029 年、2034 年
• 胰岛素
• 生长激素
• 酵素替代疗法
• 其他胜肽和蛋白质
• 全球吸入式生技药品市场，依疫苗类型细分，绩效及预测，2019-2024 年、2024-2029 年、2034 年
• 流感疫苗
• 其他呼吸道疫苗
• 全球吸入式生技药品市场，依单株抗体类型细分，绩效及预测，2019-2024 年、2024-2029 年、2034 年
• 呼吸道单株抗体
• 免疫调节单株抗体
• 其他单株抗体
• 全球可吸入生技药品市场，依基于 RNAi 的治疗类型细分，绩效及预测，2019-2024 年、2024-2029 年、2034 年
• 基于RNA的呼吸系统疾病药物
• 其他基于RNAi的治疗方法
• 全球可吸入生技药品市场及其他细分市场，依类型、实际及预测，2019-2024 年、2024-2029 年、2034 年
• 基因治疗
• 吸入小分子
• 其他创新吸入生技药品

第七章 区域和国家分析

• 全球可吸入生技药品市场各地区、表现及预测（2019-2024、2024-2029、2034）
• 全球可吸入生技药品市场（依国家/地区划分）、绩效及预测（2019-2024 年、2024-2029 年、2034 年）

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章竞争格局与公司概况

• 可吸入生技药品市场：竞争格局
• 可吸入生技药品市场：公司简介
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

第31章 其他大型创新企业

• Medtronic PLC
• Moderna Inc.
• Pfizer Inc. and BioNTech SE
• Teva Pharmaceuticals
• Baxter International
• Lonza Group AG
• CanSino Biologics Inc.
• Cipla Ltd.
• Insmed Incorporated
• Kamada Pharmaceuticals
• Vectura Group plc
• F. Hoffmann-La Roche Ltd
• Iconovo AB
• Synairgen plc
• Ab Initio Pharma LLC

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章 高市场潜力国家、细分市场与策略

• 2029年可吸入生技药品市场：提供新机会的国家
• 2029年可吸入生技药品市场：细分市场带来新机会
• 可吸入生技药品2029年：成长策略
  • 基于市场趋势的策略
  • 竞争对手的策略

第36章 附录

Inhalable biologics are biologic drugs that are delivered through the respiratory tract via inhalation. This method allows for targeted treatment of lung diseases or systemic therapy by directly reaching the lungs, which enhances the drug's effectiveness and minimizes side effects.

The primary types of inhalable biologics include peptides and proteins, vaccines, monoclonal antibodies, RNAi-based therapeutics, and others. Peptide and protein therapeutics are bioactive molecules designed to influence specific cellular pathways or replace deficient proteins. These biologics are available in various dosage forms, such as dry powder inhalers, metered-dose inhalers, nebulizers, and others, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. They are used in the treatment of respiratory diseases, diabetes, cancer, and other conditions.

The inhalable biologics market research report is one of a series of new reports from The Business Research Company that provides inhalable biologics market statistics, including inhalable biologics industry global market size, regional shares, competitors with an inhalable biologics market share, detailed inhalable biologics market segments, market trends and opportunities, and any further data you may need to thrive in the inhalable biologics industry. This inhalable biologic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The inhalable biologics market size has grown rapidly in recent years. It will grow from $2.79 billion in 2024 to $3.25 billion in 2025 at a compound annual growth rate (CAGR) of 16.4%. The growth during the historic period can be attributed to the rising prevalence of respiratory diseases globally, a growing demand for non-invasive delivery methods, increased awareness of the benefits of biologics, and the expanding research and investment in biopharmaceuticals.

The inhalable biologics market size is expected to see rapid growth in the next few years. It will grow to $5.90 billion in 2029 at a compound annual growth rate (CAGR) of 16.0%. The growth during the forecast period can be attributed to the increasing global aging population, the expansion of healthcare infrastructure in emerging markets, growing regulatory support for biologics therapy, and a rise in cases of infectious respiratory diseases. Key trends expected during this period include advancements in drug delivery systems, the integration of smart inhaler technology, innovations in aerosol science, developments in biologic drug formulations, and progress in nanoparticle-based carriers.

The growing prevalence of respiratory disorders is expected to significantly contribute to the growth of the inhalable biologics market in the coming years. Respiratory disorders encompass diseases and conditions affecting the lungs and other components of the respiratory system, including the airways, nasal passages, and lungs. The rise in these conditions is largely attributed to increasing air pollution, which exacerbates ailments such as asthma, chronic obstructive pulmonary disease (COPD), and lung cancer by exposing individuals to harmful particulate matter and pollutants. Inhalable biologics are particularly effective for these conditions as they deliver targeted treatments directly to the lungs, reducing inflammation and improving lung function with fewer systemic side effects. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency in Australia, reported that in 2023, COPD accounted for 3.6% of the total disease burden and 50% of the respiratory disease burden. Consequently, the rise in respiratory disorders is significantly boosting the inhalable biologics market.

Leading companies in the inhalable biologics market are focusing on developing groundbreaking solutions, such as inhaled insulin, to enhance patient compliance and provide faster glycemic control. Inhaled insulin is a form of insulin that is delivered directly into the bloodstream through the lungs via inhalation, rather than through injections or insulin pumps. This method involves inhaling a powder or aerosolized insulin, which is absorbed through the lungs and quickly enters the bloodstream to regulate blood sugar levels. For example, in February 2025, Cipla Limited, an India-based pharmaceutical company, received regulatory approval from the Central Drugs Standard Control Organization for Afrezza, the world's fastest inhaled insulin, offering a needle-free option for adults with type 1 and type 2 diabetes. This ultra-rapid-acting insulin works within 12 to 15 minutes of inhalation, closely mimicking the natural insulin response to meals and improving blood sugar control. Inhaled insulin presents a more comfortable alternative to daily injections, especially for patients with injection anxiety, enhancing adherence to insulin therapy.

In June 2022, Kindeva Drug Delivery Limited, a US-based pharmaceutical company, acquired iPharma Labs Inc. for an undisclosed amount. This acquisition allows Kindeva to integrate iPharma's expertise in inhalation formulations and early-stage drug development with its global capabilities in developing, commercializing, and manufacturing inhaled therapies. This combination strengthens Kindeva's position, enabling it to offer a more comprehensive, end-to-end solution for the development and manufacturing of respiratory medicines. iPharma Labs is a US-based contract research organization specializing in developing and formulating inhaled therapies, including inhalable biologics.

Major players in the inhalable biologics market are Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Medtronic PLC, Moderna Inc., Pfizer Inc. and BioNTech SE, Teva Pharmaceuticals, Baxter International, Lonza Group AG, CanSino Biologics Inc., Cipla Ltd., Insmed Incorporated, Kamada Pharmaceuticals, Vectura Group plc, F. Hoffmann-La Roche Ltd, Iconovo AB, Synairgen plc, Ab Initio Pharma LLC, Nanopharm Ltd, Ocugen Inc., MannKind Corporation.

North America was the largest region in the inhalable biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inhalable biologics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the inhalable biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The inhalable biologics market consists of sales of inhaled antibodies, inhalable mRNA-based therapeutics, inhaled vaccines, inhaled enzyme replacement therapies, and inhalable gene therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Inhalable Biologics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on inhalable biologics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for inhalable biologics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The inhalable biologics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Peptides And Proteins; Vaccines; Monoclonal Antibodies; RNAi-Based Therapeutics; Other Types
• 2) By Dosage Form: Dry Powder Inhalers; Metered Dose Inhalers; Nebulizers; Other Dosage Forms
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 4) By Application: Respiratory Diseases; Diabetes; Cancer; Other Applications
• Subsegments:
• 1) By Peptides And Proteins: Insulin; Growth Hormones; Enzyme Replacement Therapies; Other Peptides And Proteins
• 2) By Vaccines: Influenza Vaccines; Other Respiratory Vaccines
• 3) By Monoclonal Antibodies: Respiratory Monoclonal Antibodies; Immunomodulatory Monoclonal Antibodies; Other Monoclonal Antibodies
• 4) By RNAi-Based Therapeutics: RNA-Based Drugs For Respiratory Diseases; Other RNAi-Based Therapeutics
• 5) By Other Types: Gene Therapies; Small Molecule Inhalable Drugs; Other Innovative Inhalable Biologics
• Companies Mentioned: Bayer AG; Sanofi SA; AstraZeneca plc; Novartis AG; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Inhalable Biologics Market Characteristics

3. Inhalable Biologics Market Trends And Strategies

4. Inhalable Biologics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Inhalable Biologics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Inhalable Biologics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Inhalable Biologics Market Growth Rate Analysis
• 5.4. Global Inhalable Biologics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Inhalable Biologics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Inhalable Biologics Total Addressable Market (TAM)

6. Inhalable Biologics Market Segmentation

• 6.1. Global Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peptides And Proteins
• Vaccines
• Monoclonal Antibodies
• RNAi-Based Therapeutics
• Other Types
• 6.2. Global Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dry Powder Inhalers
• Metered Dose Inhalers
• Nebulizers
• Other Dosage Forms
• 6.3. Global Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Inhalable Biologics Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Respiratory Diseases
• Diabetes
• Cancer
• Other Applications
• 6.5. Global Inhalable Biologics Market, Sub-Segmentation Of Peptides And Proteins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulin
• Growth Hormones
• Enzyme Replacement Therapies
• Other Peptides And Proteins
• 6.6. Global Inhalable Biologics Market, Sub-Segmentation Of Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Influenza Vaccines
• Other Respiratory Vaccines
• 6.7. Global Inhalable Biologics Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Respiratory Monoclonal Antibodies
• Immunomodulatory Monoclonal Antibodies
• Other Monoclonal Antibodies
• 6.8. Global Inhalable Biologics Market, Sub-Segmentation Of RNAi-Based Therapeutics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• RNA-Based Drugs For Respiratory Diseases
• Other RNAi-Based Therapeutics
• 6.9. Global Inhalable Biologics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gene Therapies
• Small Molecule Inhalable Drugs
• Other Innovative Inhalable Biologics

7. Inhalable Biologics Market Regional And Country Analysis

• 7.1. Global Inhalable Biologics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Inhalable Biologics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Inhalable Biologics Market

• 8.1. Asia-Pacific Inhalable Biologics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Inhalable Biologics Market

• 9.1. China Inhalable Biologics Market Overview
• 9.2. China Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Inhalable Biologics Market

• 10.1. India Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Inhalable Biologics Market

• 11.1. Japan Inhalable Biologics Market Overview
• 11.2. Japan Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Inhalable Biologics Market

• 12.1. Australia Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Inhalable Biologics Market

• 13.1. Indonesia Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Inhalable Biologics Market

• 14.1. South Korea Inhalable Biologics Market Overview
• 14.2. South Korea Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Inhalable Biologics Market

• 15.1. Western Europe Inhalable Biologics Market Overview
• 15.2. Western Europe Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Inhalable Biologics Market

• 16.1. UK Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Inhalable Biologics Market

• 17.1. Germany Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Inhalable Biologics Market

• 18.1. France Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Inhalable Biologics Market

• 19.1. Italy Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Inhalable Biologics Market

• 20.1. Spain Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Inhalable Biologics Market

• 21.1. Eastern Europe Inhalable Biologics Market Overview
• 21.2. Eastern Europe Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Inhalable Biologics Market

• 22.1. Russia Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Inhalable Biologics Market

• 23.1. North America Inhalable Biologics Market Overview
• 23.2. North America Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Inhalable Biologics Market

• 24.1. USA Inhalable Biologics Market Overview
• 24.2. USA Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Inhalable Biologics Market

• 25.1. Canada Inhalable Biologics Market Overview
• 25.2. Canada Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Inhalable Biologics Market

• 26.1. South America Inhalable Biologics Market Overview
• 26.2. South America Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Inhalable Biologics Market

• 27.1. Brazil Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Inhalable Biologics Market

• 28.1. Middle East Inhalable Biologics Market Overview
• 28.2. Middle East Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Inhalable Biologics Market

• 29.1. Africa Inhalable Biologics Market Overview
• 29.2. Africa Inhalable Biologics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Inhalable Biologics Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Inhalable Biologics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Inhalable Biologics Market Competitive Landscape And Company Profiles

• 30.1. Inhalable Biologics Market Competitive Landscape
• 30.2. Inhalable Biologics Market Company Profiles
  • 30.2.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Inhalable Biologics Market Other Major And Innovative Companies

• 31.1. Medtronic PLC
• 31.2. Moderna Inc.
• 31.3. Pfizer Inc. and BioNTech SE
• 31.4. Teva Pharmaceuticals
• 31.5. Baxter International
• 31.6. Lonza Group AG
• 31.7. CanSino Biologics Inc.
• 31.8. Cipla Ltd.
• 31.9. Insmed Incorporated
• 31.10. Kamada Pharmaceuticals
• 31.11. Vectura Group plc
• 31.12. F. Hoffmann-La Roche Ltd
• 31.13. Iconovo AB
• 31.14. Synairgen plc
• 31.15. Ab Initio Pharma LLC

32. Global Inhalable Biologics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Inhalable Biologics Market

34. Recent Developments In The Inhalable Biologics Market

35. Inhalable Biologics Market High Potential Countries, Segments and Strategies

• 35.1 Inhalable Biologics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Inhalable Biologics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Inhalable Biologics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer